Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 16:00:46 2024-06-27 EDT 5-day change 1st Jan Change
129.8 USD -1.28% Intraday chart for Merck & Co., Inc. +0.12% +19.08%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC DJ
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug RE
Merck: FDA response on patritumab deruxtecan CF
Aqilion Announces the Termination of the Licensing and Collaboration Agreement with Merck for the Joint Development of the TAK1 Programme Taking Aim at Chronic Inflammation CI
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer CI
Merck: US approval for canine flu vaccine CF
Merck's Animal Health Unit Says USDA Approves Dog Flu Vaccine MT
Merck Animal Division's Dog Flu Treatment Gets Agriculture Department Approval DJ
China grants license to Merck's KEYTRUDA for stomach cancer treatment RE
Global markets live: Shell, UBS, Boeing, Berkshire Hathaway, Exxon... Our Logo
Merck: FDA approves Capvaxive pneumococcal vaccine CF
Merck: new FDA approval for Keytruda CF
Big tech still runs the show Our Logo
Sector Update: Health Care Stocks Flat to Lower Premarket Tuesday MT
Wall Street set for flat open after soft retail sales data RE
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals MT
Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment MT
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer DJ
US FDA approves Merck's pneumococcal vaccine for adults RE
Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults CI
Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma CI
FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease DJ
High-risk health workers can get routine Ebola vaccine, Gavi says RE
AbbVie inks immune disorder drug licensing deal with China's FutureGen RE
High-risk health workers can get routine Ebola vaccine, says Gavi RE
Chart Merck & Co., Inc.
More charts
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
131.5 USD
Average target price
142.7 USD
Spread / Average Target
+8.50%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Merck Begins Tender Offer to Acquire Imago BioSciences